Skip to main content

Table 3 Clinical profiles and sequenced hRasGRP4 cDNAs of the patients and healthy controls whose peripheral blood samples were obtained simultaneously as those in Figure 4A

From: Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis

  Age Sex DAS28 Treatment Clone 1 Clone 2 Clone 3 Clone 4 Clone 5
Healthy 1 32 F 0 none FL FL Variant 5 FL FL
Healthy 2 31 F 0 none FL FL Variant 5 Variant 6 FL
Healthy 3 38 F 0 none FL FL Variant 7 FL FL
Healthy 4 38 F 0 none FL FL FL FL  
RA 1 70 M 3.22 MTX 8 mg/week
+ IFX
FL FL FL Variant 6 FL
RA 2 66 F 3.82 MTX 6 mg/week FL FL FL Variant 6 Variant 2
RA 3 61 F 2.17 MTX 10.5 mg/week
+ TAC 3 mg/day
Variant 5 Variant 5 Variant 5 Variant 5 Variant 5
RA 4 33 F 4.87 MTX 8 mg/week
+ PSL 5 mg/day
Variant 5 FL Variant 5 FL Variant 5
RA 5 78 M 2.65 MTX 6 mg/week
+ SSZ 1000 mg/day
FL Variant6 Variant 5 Variant 5 Variant 6
RA 6 53 F 2.27 MTX 10 mg/week
+ PSL 2 mg/day
Variant 5 Variant 5 Variant 5 Variant 5 Variant 5
  1. DAS28, The Disease Activity Score in 28 joints; FL, full-length; IFX, infliximab; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; SSZ, sulphasalazine; TAC, tacrolimus.